SCHEMBL10150840

SCHEMBL10150840

Cc1ccc(/C(=N/OS(=O)(=O)C(F)(F)C(=O)OC23CC4CC(C2)C(=O)C(C4)C3)C(F)(F)C(F)(F)C(F)(F)F)cc1

nearest known ligand 0.36

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.36
TSHR P16473 1/20 0.36
RAB9A P51151 1/20 0.34
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP17A1 P05093 1/20 0.31
CYP19A1 P11511 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150820 0.83 TSHR (0.38) NPSR1TSHRCYP17A1CYP19A1
SCHEMBL10150846 0.79 TSHR (0.35) NPSR1TSHR
SCHEMBL26190608 0.74 TSHR (0.48) NPSR1TSHRCYP17A1CYP19A1
SCHEMBL11982618 0.73 CA2 (0.37) ALDH1A1HTT
SCHEMBL19261603 0.72 TSHR (0.52) NPSR1TSHRALDH1A1CYP17A1CYP19A1
SCHEMBL547287 0.72 TSHR (0.52) NPSR1TSHRALDH1A1CYP17A1CYP19A1
SCHEMBL4373737 0.71 NPSR1 (0.48) NPSR1TSHRRAB9AMEN1ALDH1A1
SCHEMBL10150821 0.71 TSHR (0.51) NPSR1TSHRCYP17A1CYP19A1
SCHEMBL786680 0.70 TSHR (0.46) NPSR1TSHRCYP17A1CYP19A1
SCHEMBL1593389 0.70 TSHR (0.41) NPSR1TSHRRAB9AALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173350-B2 Oxime compound and resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same CYC1, UQCRB, CBR1 NPSR1 2324/4885TSHR 841/4885RAB9A 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.